<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The current prognosis and classification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> relies on staging systems that integrate histopathologic and clinical findings </plain></SENT>
<SENT sid="1" pm="."><plain>However, in the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases, cell dysfunction is the result of numerous mutations that modify protein expression and post-translational modification(1) </plain></SENT>
<SENT sid="2" pm="."><plain>A number of cell surface antigens, including cluster of differentiation (CD) antigens, have been identified as potential prognostic or metastatic biomarkers in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>These antigens make ideal biomarkers as their expression often changes with <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> or interactions with other cell types, such as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-infiltrating lymphocytes (TILs) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-associated macrophages (TAMs) </plain></SENT>
<SENT sid="4" pm="."><plain>The use of immunohistochemistry (IHC) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> sub-classification and prognostication is well established for some <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types(2,3) </plain></SENT>
<SENT sid="5" pm="."><plain>However, no single 'marker' has shown prognostic significance greater than clinico-pathological staging or gained wide acceptance for use in routine pathology reporting of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases </plain></SENT>
<SENT sid="6" pm="."><plain>A more recent approach to prognostic stratification of disease phenotypes relies on surface protein profiles using multiple 'markers' </plain></SENT>
<SENT sid="7" pm="."><plain>While expression profiling of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> using proteomic techniques such as iTRAQ is a powerful tool for the discovery of biomarkers4, it is not optimal for routine use in diagnostic laboratories and cannot distinguish different cell types in a mixed population </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, large amounts of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> tissue are required for the profiling of purified plasma membrane <z:chebi fb="0" ids="17089">glycoproteins</z:chebi> by these methods </plain></SENT>
<SENT sid="9" pm="."><plain>In this video we described a simple method for surface proteome profiling of viable cells from disaggregated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples using a DotScan <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> antibody microarray </plain></SENT>
<SENT sid="10" pm="."><plain>The 122-antibody microarray consists of a standard 82-antibody region recognizing a range of lineage-specific leukocyte markers, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules, receptors and markers of <z:mp ids='MP_0001845'>inflammation</z:mp> and immune response(5), together with a satellite region for detection of 40 potentially prognostic markers for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Cells are captured only on antibodies for which they express the corresponding antigen </plain></SENT>
<SENT sid="12" pm="."><plain>The cell density per dot, determined by optical scanning, reflects the proportion of cells expressing that antigen, the level of expression of the antigen and affinity of the antibody(6) </plain></SENT>
<SENT sid="13" pm="."><plain>For <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissue or <z:mpath ids='MPATH_458'>normal</z:mpath> intestinal mucosa, optical scans reflect the immunophenotype of mixed populations of cells </plain></SENT>
<SENT sid="14" pm="."><plain>Fluorescence multiplexing can then be used to profile selected sub-populations of cells of interest captured on the array </plain></SENT>
<SENT sid="15" pm="."><plain>For example, Alexa 647-anti-epithelial cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (EpCAM; CD326), is a pan-epithelial differentiation antigen that was used to detect <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and also epithelial cells of <z:mpath ids='MPATH_458'>normal</z:mpath> intestinal mucosa, while Phycoerythrin-anti-CD3, was used to detect infiltrating T-cells(7) </plain></SENT>
<SENT sid="16" pm="."><plain>The DotScan <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> microarray should be the prototype for a diagnostic alternative to the anatomically-based <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> staging system </plain></SENT>
</text></document>